Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel.

Slides:

Advertisements

Similar presentations

Volume 55, Issue 1, Pages 1-8 (January 2009)

Advertisements

Volume 59, Issue 2, Pages (February 2011)

Volume 68, Issue 6, Pages (December 2015)

Volume 65, Issue 3, Pages (March 2014)

Volume 58, Issue 5, Pages (November 2010)

Volume 56, Issue 6, Pages (December 2009)

Volume 70, Issue 6, Pages (December 2016)

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer Francesco Cantiello, Giorgio.

European Urology Oncology

Volume 67, Issue 4, Pages (April 2015)

European Urology Oncology

Volume 60, Issue 6, Pages (December 2011)

Volume 61, Issue 2, Pages (February 2012)

Volume 52, Issue 4, Pages (October 2007)

European Urology Oncology

Volume 59, Issue 2, Pages (February 2011)

Survival outcomes and interval between lymphoscintigraphy and SLNB in cutaneous melanoma- findings of a large prospective cohort study Fionnuala M. O'Leary,

Volume 68, Issue 5, Pages (November 2015)

Volume 67, Issue 2, Pages (February 2015)

Volume 68, Issue 5, Pages (November 2015)

Volume 65, Issue 3, Pages (March 2014)

Volume 62, Issue 1, Pages (July 2012)

Volume 68, Issue 3, Pages (September 2015)

Volume 67, Issue 3, Pages (March 2015)

European Urology Oncology

Volume 71, Issue 6, Pages (June 2017)

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 53, Issue 4, Pages (April 2008)

Luis Martínez-Piñeiro European Urology Supplements

Volume 66, Issue 5, Pages (November 2014)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Validation of Preoperative Nomograms Predicting Lymph Node Involvement in Prostate Cancer: A Bi-institutional Study Alexander I. Hinev, Vesselin I. Hadjiev,

Volume 61, Issue 2, Pages (February 2012)

Volume 66, Issue 2, Pages (August 2014)

Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter,

Volume 71, Issue 1, Pages (January 2017)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Volume 153, Issue 3, Pages e16-e17 (September 2017)

Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective,

European Urology Oncology

Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,

Volume 52, Issue 6, Pages (December 2007)

European Urology Oncology

Volume 71, Issue 5, Pages (May 2017)

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA Nawar Hanna, Quoc-Dien Trinh,

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

European Urology Oncology

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

Mixed venous oxygen saturation predicts short- and long-term outcome after coronary artery bypass grafting surgery: a retrospective cohort analysis J.

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

European Urology Oncology

Volume 74, Issue 6, Pages (December 2018)

European Urology Oncology

European Urology Oncology

Axel Heidenreich European Urology Supplements

European Urology Oncology

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Fernando P. Secin, Fernando J. Bianco, Nicholas T

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

European Urology Oncology

European Urology Oncology

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Maximilian Burger, Ashish M. Kamat, David McConkey

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Presentation transcript:

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel Semjonow, Hanna Vasarainen, Teemu D. Laajala, Gennaro Musi, Ottavio de Cobelli, Tuomas Mirtti, Antti Rannikko European Urology Oncology Volume 1, Issue 4, Pages 268-275 (September 2018) DOI: 10.1016/j.euo.2018.04.006 Copyright © 2018 Terms and Conditions

Fig. 1 Calculation of cumulative cancer locations (CCLO). (A) Locations from a standard biopsy procedure are dichotomized as positive or negative. (B) Positive locations from both diagnostic and confirmatory biopsies are summed to generate CCLO. European Urology Oncology 2018 1, 268-275DOI: (10.1016/j.euo.2018.04.006) Copyright © 2018 Terms and Conditions

Fig. 2 Survival analyses by CCLO risk stratification in the pooled cohort. Kaplan-Meier survival curves for CCLO risk groups for (A) protocol-based discontinuation (PBD), (B) Gleason upgrading (GU), and (C) adverse radical prostatectomy findings (ARFP). CCLO=Cumulative Cancer Locations. European Urology Oncology 2018 1, 268-275DOI: (10.1016/j.euo.2018.04.006) Copyright © 2018 Terms and Conditions

Fig. 3 Discriminatory analyses of CCLO risk groups versus the number of positive cores in confirmatory biopsy (CBx) for the pooled cohort. Receiver operating characteristic area under the curve (AUC) and 95% confidence interval for (A) protocol-based discontinuation, (B) Gleason upgrading, and (C) adverse radical prostatectomy findings. Decision curve analyses for (D) protocol-based discontinuation, (E) Gleason upgrading, and (F) adverse radical prostatectomy findings. CCLO=Cumulative Cancer Locations. European Urology Oncology 2018 1, 268-275DOI: (10.1016/j.euo.2018.04.006) Copyright © 2018 Terms and Conditions